- Home
- ARMK vs JAZZ Comparison
ARMK vs JAZZ Comparison
Compare ARMK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | JAZZ |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | Ireland |
| Employees | 278390 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 16.1B |
| IPO Year | 2013 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ARMK | JAZZ |
|---|---|---|
| Price | $53.70 | $215.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 22 |
| Target Price | $68.53 | ★ $295.36 |
| AVG Volume (30 Days) | ★ 2.4M | 744.8K |
| Earning Date | 11-16-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 23.23 | N/A |
| EPS | 1.11 | ★ 7.17 |
| Revenue | ★ $18,506,299,000.00 | $1,618,693,000.00 |
| Revenue This Year | $8.68 | $11.00 |
| Revenue Next Year | $8.98 | $5.89 |
| P/E Ratio | $50.32 | ★ $28.98 |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $35.07 | $128.80 |
| 52 Week High | $62.65 | $266.38 |
Technical Indicators
Market Signals| Indicator | ARMK | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 44.79 |
| Support Level | $52.70 | $194.77 |
| Resistance Level | $54.36 | $241.39 |
| Average True Range (ATR) | 1.57 | 5.70 |
| MACD | 0.08 | 0.67 |
| Stochastic Oscillator | 41.81 | 80.62 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, is a foodservice company that provides facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving clients such as schools, healthcare facilities, and entertainment venues.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.